• English
    • Norsk
  • English 
    • English
    • Norsk
  • Administration
View Item 
  •   Home
  • Det matematisk-naturvitenskapelige fakultet
  • Institutt for biovitenskap
  • Institutt for biovitenskap
  • View Item
  •   Home
  • Det matematisk-naturvitenskapelige fakultet
  • Institutt for biovitenskap
  • Institutt for biovitenskap
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Activation of antitumor M1 macrophages for cancer immunotherapy

Müller, Elisabeth
Doctoral thesis
View/Open
ElisabethMueller-PhD-2018.pdf (20.36Mb)
Year
2018
Permanent link
http://urn.nb.no/URN:NBN:no-67158

Metadata
Show metadata
Appears in the following Collection
  • Institutt for biovitenskap [589]
Abstract
The last few years have seen the arrival of new effective cancer therapies which is directed at the immune system rather than the cancer cells directly. One type of cancer immunotherapies is the so-called checkpoint inhibitors, which function by releasing a break on the immune response against cancer cells. Although resulting in impressive results, certain patients remain unresponsive and new strategies for immunotherapies are needed.

In her PhD project, Elisabeth Müller has been searching for a switch that could get a part of the body’s immune cells started fighting cancer cells. She has found several new molecular combinations that are able to activate antitumor functions of macrophages in vitro. Her findings may result in the development of better strategies for delivering active drugs specifically to the macrophages in tumors. Such strategies include the use of viral vectors that specifically infect tumor cells and drugs that are encapsulated into nanoparticles. Once tested and confirmed in vivo, activation of antitumor macrophages could be an important treatment strategy for patients that do not respond sufficiently to checkpoint inhibitors, or in combination with therapeutic cancer vaccines which are not effective as monotherapy.

Elisabeth Müller and her colleagues were able to find several compounds, called TLR agonists that activate macrophages when combined with the protein interferon-γ (IFN-γ). These macrophages produce a toxic compound called nitric oxide and prevent cancer cells from growing in vitro. However, it has previously been proven difficult to treat patients with effective doses of IFN-γ without causing harmful side effects. This thesis describes a new way to deliver IFN-γ to the tumor only using viral vectors that specifically infect cancer cells. Upon infection, the cancer cells are programmed to produce and secrete IFN-γ, before later dying. The IFN-γ produced was able to activate antitumor macrophages when combined with TLR agonists. These viral vectors will be tested in vivo for their ability to infect cancer cells in growing tumors and activate a macrophage-mediated antitumor immune response.

In her last paper, Elisabeth Müller and colleagues discovered that two other proteins, IFN-α and IFN-β, can activate macrophages in a similar way as IFN-γ. As macrophages can produce their own IFN-α and IFN-β, this opens up for new ways to make macrophages inhibit cancer cell growth. Müller replaced these proteins altogether with a combination of two TLR agonists, one of which made the macrophages produce IFN-α and IFN-β. This TLR agonist, poly(I:C), also was encapsulated into highly effective nanoparticles, which are taken up specifically by macrophages. Such nanoparticles have the potential to improve the accuracy of drug delivery to tumors and will be tested in animal models in the future.
List of papers
Paper I: Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages. Elisabeth Müller, Panagiotis F. Christopoulos, Sanjib Halder, Anna Lunde, Kahsai Beraki, Martin Speth, Inger Øynebråten and Alexandre Corthay. Frontiers in Immunology 8:1383 (2017). The article is included in the thesis. Also available at: http://urn.nb.no/URN:NBN:no-62150
Paper II: Generation and Functional In Vitro Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ. Baiba Kurena, Elisabeth Müller, Panagiotis F. Christopoulos, Ingvild Bjellmo Johnsen, Branislava Stankovic, Inger Øynebråten, Alexandre Corthay and Anna Zajakina. Frontiers in Immunology 8:1667 (2017). The article is included in the thesis. Also available at: http://urn.nb.no/URN:NBN:no-66233
Paper III: Role of type I and type II interferons for activation of antitumor M1 macrophages. Elisabeth Müller, Martin Speth, Panagiotis F. Cristopoulos, Anna Lunde, Ajna Avdagic, Inger Øynebråten and Alexandre Corthay. Manuscript in preparation. The paper is not available in DUO awaiting publishing.
 
Responsible for this website 
University of Oslo Library


Contact Us 
duo-hjelp@ub.uio.no


Privacy policy
 

 

For students / employeesSubmit master thesisTemplatesAccess to restricted material

Browse

All of DUOCommunities & CollectionsBy Issue DateAuthorsTitlesThis CollectionBy Issue DateAuthorsTitles

For library staff

Login

Statistics

View Usage Statistics
RSS Feeds
 
Responsible for this website 
University of Oslo Library


Contact Us 
duo-hjelp@ub.uio.no


Privacy policy